Harnessing ExDNA for precision exatecan delivery in cancer: a novel antibody-drug conjugate approach [0.03%]
利用外源DNA精确递送抗癌药物exatecan：一种新型抗体药物偶联物方法
Zaira Ianniello,Huimei Lu,Elias Quijano et al.
Zaira Ianniello et al.
Background: Current antibody-drug conjugates (ADCs) face limitations due to a lack of tumor-selective targets, inefficient internalization, and challenges in reaching tumors in challenging sites, ultimately limiting their...
Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications [0.03%]
基于RNA的癌症治疗进展：前期临床与临床意义
Yubo Yan,Shuang Liu,Jie Wen et al.
Yubo Yan et al.
Cancer therapy has been revolutionised by the emergence of RNA-based therapeutics, providing several strategies and mechanisms to regulate gene expression via messenger RNA (mRNA), small interfering RNA (siRNA), microRNAs (miRNA), antisense...
Medical importance and pharmacokinetics of gold nanoparticles in the human body [0.03%]
金纳米颗粒的医学重要性及其在人体内的药代动力学性质研究
Priyanka Singh,Abhayraj S Joshi,Hina Singh et al.
Priyanka Singh et al.
Gold nanoparticles (AuNPs) have emerged as versatile nanocarriers with promising potential in therapeutic applications due to their tunable physicochemical properties, ease of functionalization, and excellent biocompatibility. Recognized as...
Immunometabolism: crosstalk with tumor metabolism and implications for cancer immunotherapy [0.03%]
肿瘤代谢与免疫代谢的相互作用及对癌症免疫治疗的影响
Huiru Zhang,Jialiang Fan,Deyang Kong et al.
Huiru Zhang et al.
Immunometabolism has established a groundbreaking paradigm for cancer immunotherapy by decoding the intricate interaction networks between metabolic pathways and immune responses. This review comprehensively explores the metabolic reprogram...
Microplastics as emerging carcinogens: from environmental pollutants to oncogenic drivers [0.03%]
微塑料：从环境污染物到致癌驱动因素的新晋致癌物
Sarvesh Kumar Mishra,Tapojyoti Sanyal,Pritha Kundu et al.
Sarvesh Kumar Mishra et al.
Emerging role of cancer-associated fibroblasts in the premetastatic niche [0.03%]
癌细胞相关成纤维细胞在前转移微环境中的作用不容忽视
Shuaixi Yang,Ying Guo,Jiachi Jia et al.
Shuaixi Yang et al.
Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions [0.03%]
克服抗PD-L1免疫治疗抵抗的机制、联合策略及未来方向
Kartik Mandal,Ganesh Kumar Barik,Manas Kumar Santra
Kartik Mandal
Cancer cells express high levels of programmed cell death-ligand 1 (PD-L1) to evade immune surveillance. PD-L1 interacts with PD-1 on T cells to make them non-functional. Thus, PD-L1 and PD-1 are pivotal targets in cancer immunotherapy. Whi...
Exosome-mediated metabolic reprogramming: effects on thyroid cancer progression and tumor microenvironment remodeling [0.03%]
外泌体介导的代谢重编程：对甲状腺癌进展和肿瘤微环境重塑的影响
Shouhua Li,Hengtong Han,Kaili Yang et al.
Shouhua Li et al.
Metabolic reprogramming is one of the fundamental characteristics of thyroid cancer (TC), which meets its energy and biosynthetic demands through mitochondrial dysfunction, glycolysis activation, lipid metabolism imbalance, and glutamine de...
MALAT1 as a molecular driver of tumor progression, immune evasion, and resistance to therapy [0.03%]
MALAT1作为肿瘤进展、免疫逃逸和治疗抵抗的分子驱动因素
Amirreza Bitaraf,Alireza Zafarani,Pardis Jahandideh et al.
Amirreza Bitaraf et al.
Long noncoding RNAs (lncRNAs) are emerging as important regulators of gene expression in both normal biological systems and disease. Among them, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) has attracted considerable atte...
Zhifei Han,Wenjuan Liu,Yigao Zhu et al.
Zhifei Han et al.
Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related deaths worldwide. It is associated with high molecular and phenotypic heterogeneity. Early-stage gastric cancer can be treated with endoscopic rese...